Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


InSphero WebEx meeting “Scaffold-Free 3D Microtissue Models.”  

 

 

InSphero WebEx meeting “Scaffold-Free 3D Microtissue Models.”

 

Wednesday, May 16, 2012, No Cost to View

 

8:30 AM to 9:30 AM, Click Here for Full Details

 

 
WebEx link for the meeting with InSphero:
1. Go to https://insphero.webex.com/insphero/j.php?ED=201338187&UID=1351687167&PW=NZTk1M2NjODll&RT=MTYjMjI%3D
2. If requested, enter your name and email address.
3. If a password is required, enter the meeting password: 12345
4. Click "Join".
 
The Dial-in number is :
USA :  +1 559 546 1700

 

PIN: 157647#

 

 
About InSphero
InSphero is a leading supplier of organotypic, biological microtissues for biomimetic drug testing. The company, headquartered in Zurich, Switzerland, currently collaborates with more than ten global pharmaceutical and cosmetics companies to implement the company’s patent-pending microtissue technology in the customer’s development work-flow. InSphero is a spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich and was founded in 2009 by Dr. Jan Lichtenberg, Dr. Jens Kelm, Dr. Wolfgang Moritz and Prof. Dr. Dr. Simon P. Hoerstrup. InSphero has its production, laboratory and office space at the Technopark in Zurich, Switzerland. InSphero was recognized for its scientific and commercial achievements with a number of awards, including the VentureKick award, Heuberger Entrepreneurial Award and CTIstartup certification.
 
InSphero’s founders combine more than 15 years of experience in microtissue engineering and over 10 years in microfluidics and laboratory automation with the goal to deliver highly functional, reliable and easy-to-use microtissues.
 
InSphero AG
Technoparkstrasse 1
CH-8005 Zurich
Switzerland
Tel.: +41-44-515049-0
Fax +41-44-515049-1

 

 

Posted on 14-May-12 by Toto, Brent
Tags: OSU Regenerative Medicine News, Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: